(56 intermediate revisions by the same user not shown)
Line 1:
Line 1:
<languages />
<languages />
<div lang="en" dir="ltr" class="mw-content-ltr">
{{Infobox medical condition (new)
{{Infobox medical condition (new)
| name =
| name =
Line 7:
Line 6:
| caption =
| caption =
| pronounce =
| pronounce =
| field = [[Endocrinology]]
| field = [[Endocrinology/ja]]
| symptoms =
| symptoms =
| complications =
| complications =
Line 24:
Line 23:
| deaths =
| deaths =
}}
}}
'''Insulin resistance''' ('''IR''') is a [[pathological]] condition in which [[cell (biology)|cells]] either fail to respond normally to the hormone [[insulin]] or [[downregulation|downregulate]] insulin receptors in response to [[hyperinsulinemia]].
Insulin is a hormone that facilitates the transport of glucose from blood into cells, thereby reducing blood [[glucose]] (blood sugar). Insulin is released by the [[pancreas]] in response to carbohydrates consumed in the diet. In states of insulin resistance, the same amount of insulin does not have the same effect on glucose transport and blood sugar levels. There are many causes of insulin resistance and the underlying process is still not completely understood. Risk factors for insulin resistance include [[obesity]], [[sedentary lifestyle]], family history of diabetes, various health conditions, and certain medications. Insulin resistance is considered a component of the [[metabolic syndrome]]. There are multiple ways to measure insulin resistance such as fasting insulin levels or glucose tolerance tests, but these are not often used in clinical practice. Insulin resistance can be improved or reversed with lifestyle approaches, such as weight reduction, exercise, and dietary changes.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
==原因==
==Cause==
{{Anchor|Cause}}
===Risk factors===
===危険因子===
There are a number of risk factors for insulin resistance, including being overweight or obese or having a [[sedentary lifestyle]]. Various genetic factors can increase risk, such as a family history of diabetes, and there are some specific medical conditions associated with insulin resistance, such as [[polycystic ovary syndrome]].
米国[[:en:National Institute of Diabetes and Digestive and Kidney Diseases|国立糖尿病・消化器・腎臓病研究所]]は、インスリン抵抗性の素因となりうる特定のリスクには以下のようなものがあるとしている：
The U.S. [[National Institute of Diabetes and Digestive and Kidney Diseases]] states that specific risks that may predispose an individual to insulin resistance can include:
Dietary factors are likely to contribute to insulin resistance. However, causative foods are difficult to determine given the limitations of nutrition research. Foods that have independently been linked to insulin resistance include those high in sugar with high [[Glycemic index|glycemic indices]], low in omega-3 and fiber, and which are [[hyperpalatable]] which increases risk of overeating. Overconsumption of fat- and sugar-rich meals and beverages have been proposed as a fundamental factor behind the [[metabolic syndrome]] epidemic.
Diet also has the potential to change the ratio of polyunsaturated to [[saturated fats|saturated]] phospholipids in cell membranes. The percentage of [[polyunsaturated fatty acids]] (PUFAs) is inversely correlated with insulin resistance. It is hypothesized that increasing cell membrane fluidity by increasing PUFA concentration might result in an enhanced number of insulin receptors, an increased affinity of insulin to its receptors, and reduced insulin resistance.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
[[vitamin D/ja|ビタミンD]]の欠乏もインスリン抵抗性と関連している。
[[Vitamin D]] deficiency has also been associated with insulin resistance.
Sedentary lifestyle increases the likelihood of development of insulin resistance. In epidemiological studies, higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%.
Studies have consistently shown that there is a link between insulin resistance and circadian rhythm, with insulin sensitivity being higher in the morning and lower in the evening. A mismatch between the [[circadian rhythm]] and the meals schedule, such as in [[circadian rhythm disorder]]s, may increase insulin resistance.
Some medications are associated with insulin resistance including [[corticosteroid]]s, [[protease inhibitors]] (type of HIV medication), and [[atypical antipsychotic]]s.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
===睡眠中に光を浴びること===
===Exposure to light during sleep===
睡眠中に光を浴びることは、インスリン抵抗性を引き起こし、心拍数を増加させることが示されている。
Being exposed to light during sleep has been shown to cause insulin resistance and increase heart rate.
Cortisol counteracts [[insulin]] and can lead to increased hepatic [[gluconeogenesis]], reduced peripheral utilization of glucose, and increased insulin resistance. It does this by decreasing the translocation of [[glucose transporter]]s (especially [[GLUT4]]) to the cell membrane.
Based on the significant improvement in insulin sensitivity in humans after [[bariatric surgery]] and rats with surgical removal of the duodenum, it has been proposed that some substance is produced in the [[mucosa]] of that initial portion of the small intestine that signals body cells to become insulin resistant. If the producing tissue is removed, the signal ceases and body cells revert to normal insulin sensitivity. No such substance has been found as yet, and the existence of such a substance remains speculative.
[[PCOS|Polycystic ovary syndrome]] and [[NAFLD|non-alcoholic fatty liver disease (NAFLD)]] are associated with insulin resistance. [[Hepatitis C]] also makes people three to four times more likely to develop type 2 diabetes and insulin resistance.
Multiple studies involving different methodology suggest that impaired function of [[Mitochondrion|mitochondria]] might play a pivotal role in the pathogenesis of insulin resistance. Mitochondrial dysfunction may result from the formation of [[reactive oxygen species]], genetic factors, aging, and reduced mitochondrial biogenesis. If confirmed by rigorous studies, a link between mitochondrial disorders and reduced insulin sensitivity might pave the way to new therapeutic approaches.
Acute or chronic inflammation, such as in infections, can cause insulin resistance. [[tumor necrosis factor-alpha|TNF-α]] is a cytokine that may promote insulin resistance by promoting [[lipolysis]], disrupting insulin signaling, and reducing the expression of GLUT4.
Several genetic loci have been determined to be associated with insulin insensitivity. This includes variation in loci near the NAT2, GCKR, and IGFI genes associated with insulin resistance. Further research has shown that loci near the genes are linked to insulin resistance. However, these loci are estimated to account for only 25–44% of the genetic component of insulin resistance.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
==病態生理学==
==Pathophysiology==
{{Anchor|Pathophysiology}}
In normal metabolism, the elevated blood glucose instructs beta (β) cells in the [[Islets of Langerhans]], located in the [[pancreas]], to release insulin into the blood. The insulin makes insulin-sensitive tissues in the body (primarily skeletal [[muscle]] cells, [[adipose]] tissue, and [[liver]]) absorb [[glucose]] which provides energy as well as lowers blood glucose. The beta cells reduce insulin output as the blood glucose level falls, allowing blood glucose to settle at a constant of approximately 5 mmol/L (90 mg/dL). In an ''insulin-resistant'' person, normal levels of insulin do not have the same effect in controlling blood glucose levels.
正常な代謝では、上昇した血中グルコースは、[[pancreas/ja|膵臓]]にある[[Islets of Langerhans/ja|ランゲルハンス島]]のβ細胞にインスリンを血液中に放出するように指示する。インスリンは体内のインスリン感受性組織（主に骨格[[muscle/ja|筋肉]]細胞、[[adipose/ja|脂肪]]組織、[[liver/ja|肝臓]]）に[[glucose/ja|グルコース]]を吸収させ、エネルギーを供給すると同時に血糖値を下げる。β細胞は血糖値が下がるとインスリンの分泌を減らし、血糖値を約5 mmol/L（90 mg/dL）に一定に保つ。インスリン抵抗性」では、正常レベルのインスリンでは血糖値をコントロールする効果はない。
When the body produces insulin under conditions of insulin resistance, the cells are unable to absorb or use it as effectively and it stays in the bloodstream. Certain cell types such as [[fat]] and [[muscle]] cells require insulin to absorb glucose and when these cells fail to respond adequately to circulating insulin, blood glucose levels rise. The [[liver]] normally helps regulate glucose levels by reducing its secretion of glucose in the presence of insulin. However, in insulin resistance, this normal reduction in the liver's glucose production may not occur, further contributing to elevated blood glucose.
Insulin resistance in [[adipose tissue|fat cells]] results in reduced uptake of circulating lipids and increased [[hydrolysis]] of stored [[triglyceride]]s. This leads to elevated free [[fatty acid]]s in the [[blood plasma]] and can further worsen insulin resistance. Since insulin is the primary hormonal signal for energy storage into [[fat cells]], which tend to retain their sensitivity in the face of hepatic and skeletal muscle resistance, insulin resistance stimulates the formation of new fatty tissue and accelerates weight gain.
In states of insulin resistance, [[beta cell]]s in the [[pancreas]] increase their production of insulin. This causes [[hyperinsulinemia|high blood insulin]] (hyperinsulinemia) to compensate for the high blood glucose. During this compensated phase of insulin resistance, [[Pancreatic beta cell function|beta cell function]] is upregulated, insulin levels are higher, and blood glucose levels are still maintained. If compensatory insulin secretion fails, then either fasting (impaired fasting glucose) or postprandial (impaired glucose tolerance) glucose concentrations increase. Eventually, type 2 diabetes occurs when glucose levels become higher as the resistance increases and compensatory insulin secretion fails. The inability of the β-cells to produce sufficient insulin in a condition of hyperglycemia is what characterizes the transition from insulin resistance to type 2 diabetes.
Insulin resistance is strongly associated with intestinal-derived [[Apolipoprotein B|apoB-48]] production rate in insulin-resistant subjects and type 2 diabetics. Insulin resistance often is found in people with visceral adiposity, hypertension, hyperglycemia, and [[dyslipidemia]] involving elevated triglycerides, small dense [[low-density lipoprotein]] (sdLDL) particles, and decreased [[high-density lipoprotein]] (HDL) cholesterol levels. With respect to visceral adiposity, a great deal of evidence suggests two strong links with insulin resistance. First, unlike subcutaneous adipose tissue, visceral adipose cells produce significant amounts of proinflammatory [[cytokines]] such as tumor necrosis factor-alpha ([[TNF-a]]), and [[Interleukins]]-1 and −6, etc. In numerous experimental models, these proinflammatory cytokines disrupt normal insulin action in fat and muscle cells and may be a major factor in causing the whole-body insulin resistance observed in patients with visceral adiposity. Much of the attention on production of proinflammatory cytokines has focused on the IKK-beta/[[NF-kappa-B]] pathway, a protein network that enhances transcription of inflammatory markers and mediators that may cause insulin resistance. Second, visceral adiposity is related to an accumulation of fat in the liver, a condition known as [[non-alcoholic fatty liver disease]] (NAFLD). The result of NAFLD is an excessive release of free fatty acids into the bloodstream (due to increased lipolysis), and an increase in hepatic breakdown of glycogen stores into glucose ([[glycogenolysis]]), both of which have the effect of exacerbating peripheral insulin resistance and increasing the likelihood of [[T2DM|Type 2 diabetes mellitus]].
The excessive expansion of adipose tissue that tends to occur under sustainedly positive energy balance (as in overeating) has been postulated by [[Antonio Vidal-Puig|Vidal-Puig]] to induce lipotoxic and inflammatory effects that may contribute to causing insulin resistance and its accompanying disease states.
Also, insulin resistance often is associated with a [[hypercoagulable state]] (impaired [[fibrinolysis]]) and increased inflammatory cytokine levels.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
=== 分子メカニズム ===
=== Molecular mechanism ===
分子レベルでは、細胞はインスリン受容体を通してインスリンを感知し、そのシグナルは[[PI3K/AKT/mTOR pathway/ja|PI3K/Akt/mTORシグナル伝達経路]]として知られるシグナル伝達カスケードを通して伝播する。最近の研究では、この経路は、ある種の細胞では生理的条件下で[[Bistability/ja#In biological and chemical systems|双安定性]]スイッチとして働く可能性が示唆されており、インスリン応答は閾値現象である可能性が高い。インスリンに対する経路の感受性は、遊離脂肪酸の脂肪分解のような多くの因子によって鈍化し、インスリン抵抗性を引き起こすかもしれない。しかし、より広い観点から見ると、感受性の調整（感受性の低下を含む）は、変化する環境や代謝条件に適応するために生物がよく行うことである。例えば、妊娠は代謝条件の顕著な変化であり、その下では、母親は脳（母親の脳と胎児の脳）のためにグルコースをより多く確保するために、筋肉のインスリン感受性を低下させなければならない。これは、胎盤成長因子を分泌してインスリン受容体基質（IRS）とPI3Kの相互作用を阻害することにより、反応閾値を上げる（すなわち、感受性の発現を遅らせる）ことで達成できる。
At the molecular level, a cell senses insulin through insulin receptors, with the signal propagating through a signaling cascade collectively known as [[PI3K/AKT/mTOR pathway|PI3K/Akt/mTOR signaling pathway]]. Recent studies suggested that the pathway may operate as a [[Bistability#In biological and chemical systems|bistable]] switch under physiologic conditions for certain types of cells, and insulin response may well be a threshold phenomenon. The pathway's sensitivity to insulin may be blunted by many factors such as lipolysis of free fatty acids, causing insulin resistance. From a broader perspective, however, sensitivity tuning (including sensitivity reduction) is a common practice for an organism to adapt to the changing environment or metabolic conditions. Pregnancy, for example, is a prominent change of metabolic conditions, under which the mother has to reduce her muscles' insulin sensitivity to spare more glucose for the brains (the mother's brain and the fetal brain). This can be achieved through raising the response threshold (i.e., postponing the onset of sensitivity) by secreting placental growth factor to interfere with the interaction between insulin receptor substrate (IRS) and PI3K, which is the essence of the so-called ''adjustable threshold hypothesis'' of insulin resistance.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
インスリン抵抗性は、抗酸化防御機構として働く細胞[[mitochondria/ja|ミトコンドリア]]内の[[superoxide dismutase/ja|スーパーオキシドジスムターゼ]]による過剰な栄養に対する反応であると提唱されている。この関連は、インスリン抵抗性の多様な原因の下に存在するようである。また、インスリン抵抗性は、細胞をミトコンドリアアンカプラー、[[electron transport chain/ja|電子輸送鎖]]阻害剤、またはミトコンドリア[[superoxide dismutase mimetics/ja|スーパーオキシドジスムターゼ模倣薬]]にさらすことによって急速に回復するという知見に基づいている。
Insulin resistance has been proposed to be a reaction to excess nutrition by [[superoxide dismutase]] in cell [[mitochondria]] that acts as an antioxidant defense mechanism. This link seems to exist under diverse causes of insulin resistance. It also is based on the finding that insulin resistance may be reversed rapidly by exposing cells to mitochondrial uncouplers, [[electron transport chain]] inhibitors, or mitochondrial [[superoxide dismutase mimetics]].
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
==診断==
==Diagnosis==
{{Anchor|Diagnosis}}
===Fasting insulin levels===
===空腹時インスリン値===
A fasting serum insulin level greater than 29 microIU/mL or 174 pmol/L indicates insulin resistance. The same levels apply three hours after the last meal.
During a [[glucose tolerance test]] (GTT), which may be used to diagnose diabetes mellitus, a fasting patient takes a 75 gram oral dose of glucose. Then blood glucose levels are measured over the following two hours.
Interpretation is based on [[WHO]] guidelines. After two hours a [[blood sugar|glycemia]] less than 7.8 mmol/L (140 mg/dL) is considered normal, a glycemia of between 7.8 and 11.0 mmol/L (140 to 197 mg/dL) is considered as [[impaired glucose tolerance]] (IGT), and a glycemia of greater than or equal to 11.1 mmol/L (200 mg/dL) is considered [[diabetes mellitus]].
An [[oral glucose tolerance test]] (OGTT) may be normal or mildly abnormal in simple insulin resistance. Often, there are raised glucose levels in the early measurements, reflecting the loss of a postprandial peak (after the meal) in insulin production. Extension of the testing (for several more hours) may reveal a [[hypoglycemia|hypoglycemic]] "dip," that is a result of an overshoot in insulin production after the failure of the physiologic postprandial insulin response.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
===高インスリン血性食欲低下クランプ===
===Hyperinsulinemic euglycemic clamp===
インスリン抵抗性を調査し定量化するための[[gold standard (test)/ja|ゴールドスタンダード]]は「高インスリン血性優血クランプ」であり、[[hypoglycemia/ja|低血糖]]を起こすことなく[[insulin/ja|インスリン]]レベルの上昇を補うのに必要な[[glucose/ja|グルコース]]の量を測定することから、そう呼ばれている。[[glucose clamp technique/ja|グルコースクランプ法]]の一種である。この検査が臨床で行われることはほとんどないが、医学検査ではさまざまな医薬品の効果を評価する場合などに用いられる。グルコース注入速度は一般に糖尿病の文献ではGINF値と呼ばれている。
The [[gold standard (test)|gold standard]] for investigating and quantifying insulin resistance is the "hyperinsulinemic euglycemic clamp," so-called because it measures the amount of [[glucose]] necessary to compensate for an increased [[insulin]] level without causing [[hypoglycemia]]. It is a type of [[glucose clamp technique]]. The test is rarely performed in clinical care, but is used in medical research, for example, to assess the effects of different medications. The rate of glucose infusion commonly is referred to in diabetes literature as the GINF value.
The procedure takes about two hours. Through a [[peripheral vein]], [[insulin]] is infused at 10–120 mU per m<sup>2</sup> per [[minute]]. In order to compensate for the insulin [[intravenous|infusion]], [[glucose]] 20% is infused to maintain blood sugar levels between 5 and 5.5 mmol/L. The rate of glucose infusion is determined by checking the [[blood sugar]] levels every five to ten minutes.
The rate of glucose infusion during the last thirty minutes of the test determines insulin sensitivity. If high levels (7.5 mg/min or higher) are required, the patient is insulin-sensitive. Very low levels (4.0 mg/min or lower) indicate that the body is resistant to insulin action. Levels between 4.0 and 7.5 mg/min are not definitive, and suggest "impaired glucose tolerance," an early sign of insulin resistance.
This basic technique may be enhanced significantly by the use of glucose tracers. Glucose may be labeled with either stable or radioactive atoms. Commonly used tracers are 3-<sup>3</sup>H glucose (radioactive), 6,6 <sup>2</sup>H-glucose (stable) and 1-<sup>13</sup>C Glucose (stable). Prior to beginning the hyperinsulinemic period, a 3h tracer infusion enables one to determine the basal rate of glucose production. During the clamp, the plasma tracer concentrations enable the calculation of whole-body insulin-stimulated glucose metabolism, as well as the production of glucose by the body (i.e., endogenous glucose production).
Another measure of insulin resistance is the modified insulin suppression test developed by [[Gerald Reaven]] at Stanford University. The test correlates well with the euglycemic clamp, with less operator-dependent error. This test has been used to advance the large body of research relating to the metabolic syndrome.
Patients initially receive 25 μg of [[octreotide]] (Sandostatin) in 5 mL of normal saline over 3 to 5 minutes via intravenous infusion (IV) as an initial bolus, and then, are infused continuously with an intravenous infusion of [[somatostatin]] (0.27 μg/m<sup>2</sup>/min) to suppress endogenous insulin and glucose secretion. Next, insulin and 20% glucose are infused at rates of 32 and 267 mg/m<sup>2</sup>/min, respectively. Blood glucose is checked at zero, 30, 60, 90, and 120 minutes, and thereafter, every 10 minutes for the last half-hour of the test. These last four values are averaged to determine the steady-state plasma glucose level (SSPG). Subjects with an SSPG greater than 150 mg/dL are considered to be insulin-resistant.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
===代替法===
===Alternatives===
クランプ "法の複雑な性質（および患者によっては[[hypoglycemia/ja|低血糖]]の潜在的危険性）を考慮し、インスリン抵抗性の測定を簡略化するための代替法が模索されてきた。最初は[[homeostatic model assessment/ja|恒常性モデル評価]] (HOMA)であり、最近の方法としては[[定量的インスリン感受性チェック指標]]（QUICKI）や[[SPINA-GR/ja|SPINA-GR]]がある。これらの計算マーカーはインスリン抵抗性を計算するためにすべて[[fasting/ja|空腹時]][[insulin/ja|インスリン]]値と[[glucose/ja|グルコース]]値を用いるが、いずれもクランプ試験の結果と妥当な相関がある。
Given the complicated nature of the "clamp" technique (and the potential dangers of [[hypoglycemia]] in some patients), alternatives have been sought to simplify the measurement of insulin resistance. The first was the [[homeostatic model assessment|Homeostatic Model Assessment]] (HOMA), and more recent methods include the [[Quantitative insulin sensitivity check index]] (QUICKI) and [[SPINA-GR]], a measure for insulin sensitivity. All of these calculated markers employ [[fasting]] [[insulin]] and [[glucose]] levels to calculate insulin resistance, and all correlate reasonably with the results of clamping studies.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
==予防と管理==
==Prevention and management==
{{Anchor|Prevention and management}}
Maintaining a healthy body weight and being physically active can help reduce the risk of developing insulin resistance.
The primary treatment for insulin resistance is [[exercise]] and [[weight loss]]. Both [[metformin]] and [[thiazolidinedione]]s improve insulin sensitivity. Metformin is approved for prediabetes and type 2 diabetes and has become one of the more commonly prescribed medications for insulin resistance.
The ''Diabetes Prevention Program'' (DPP) showed that exercise and diet were nearly twice as effective as [[metformin]] at reducing the risk of progressing to type 2 diabetes. However, the participants in the DPP trial regained about 40% of the weight that they had lost at the end of 2.8 years, resulting in a similar incidence of diabetes development in both the lifestyle intervention and the control arms of the trial. In epidemiological studies, higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%.
Furthermore, physical training has also generally been seen to be an effective antagonist of insulin resistance in obese or overweight children and adolescents (under the age of 19). As per the 2016 systematic review and meta-analysis conducted by Marson et al., aerobic exercise is associated with fasting insulin reduction; however, resistance and combined exercise are not. The authors caution against demeaning the importance of resistance and combined exercise, as this type of training is generally less researched than aerobic training. Overall, physical training can be used in both adolescents and adults to prevent the progression of insulin resistance and future possible metabolic and cardiovascular disease.
[[Resistant starch]] from high-amylose corn, [[amylomaize]], has been shown to reduce insulin resistance in healthy individuals, in individuals with insulin resistance, and in individuals with type 2 diabetes.
Some types of [[Polyunsaturated fat|polyunsaturated fatty acids]] ([[omega-3]]) may moderate the progression of insulin resistance into type 2 diabetes, however, omega-3 fatty acids appear to have limited ability to reverse insulin resistance, and they cease to be efficacious once type 2 diabetes is established.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
==歴史==
==History==
{{Anchor|History}}
The concept that insulin resistance may be the underlying cause of [[diabetes mellitus]] type 2 was first advanced by Professor Wilhelm Falta and published in Vienna in 1931, however, type 2 diabetes does not occur unless there is concurrent failure of compensatory insulin secretion.
Some scholars go as far as to claim that neither insulin resistance, nor obesity really are metabolic disorders ''per se'', but simply adaptive responses to sustained caloric surplus, intended to protect bodily organs from [[lipotoxicity]] (unsafe levels of lipids in the bloodstream and tissues): "Obesity should therefore not be regarded as a pathology or disease, but rather as the normal, physiologic response to sustained caloric surplus... As a consequence of the high level of lipid accumulation in insulin target tissues including skeletal muscle and liver, it has been suggested that exclusion of glucose from lipid-laden cells is a compensatory defense against further accumulation of lipogenic substrate."
Other prevailing thoughts that insulin resistance can be an evolutionary adaptation include the [[thrifty gene hypothesis]]. This hypothesis raises the point that if there is a genetic component to insulin resistance and Type 2 diabetes, these phenotypes should be selected against. Yet, there has been an increase in mean insulin resistance in both the normoglycemic population as well as the diabetic population.
J.V. Neel postulates that originally in times of increased famine in ancient humans' ancestors, genes conferring a mechanism for increased glucose storage would be advantageous. In the modern environment today, however, this is not the case.
Evidence is contradictory to Neel in studies of the Pima Indians, which indicate that the people with higher insulin sensitives tended to weigh the most and conversely people with insulin resistance tended to weigh less on average in this demographic.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
現代の仮説では、インスリン代謝は社会生態学的適応であり、インスリンは身体の様々な構成要素へのエネルギー配分を区別する手段であり、インスリン感受性はエネルギーをどこに振り向けるかを操作する適応であるとされている。行動スイッチ仮説では、インスリン抵抗性が生殖戦略と行動方法を変える2つの方法をもたらすと仮定している。この2つの戦略は、"rからKへ "と "兵士から外交官へ "という造語である。r to K戦略では、インスリンを胎盤を介して胎児に迂回させる。これは胎児の体重増加を示しているが、母親は示しておらず、親の投資を増やす方法（K戦略）であることを示している。兵士から外交官へ」では、骨格筋のインスリンに対する感受性が低いため、インスリン受容体を必要としない脳にグルコースを迂回させることができる。これにより、様々な研究で認知発達の増加が示されている。
Modern hypotheses suggest that insulin metabolism is a socio-ecological adaptation with insulin being the means for differentiating energy allocation to various components of the body and insulin sensitivity an adaptation to manipulate where the energy is diverted to. The Behavioral Switch Hypothesis posits that insulin resistance results in two methods to alter reproductive strategies and behavioral methods. The two strategies are coined as "r to K" and "soldier to diplomat." The r to K strategy involves diverting insulin via placenta to the fetus. This has demonstrated weight gain in the fetus, but not the mother indicating a method of increased parental investment (K strategy). In the "soldier to diplomat" the insensitivity of skeletal muscle to insulin could divert the glucose to the brain, which does not require insulin receptors. This has shown increases in cognitive development across various studies.
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
== こちらも参照 ==
== See also ==
{{col div|colwidth=40em}}
{{col div|colwidth=40em}}
* [[Pancreatic beta cell function]]
* [[Pancreatic beta cell function/ja]]
* [[Chronic Somogyi rebound]]
* [[Chronic Somogyi rebound/ja]]
* [[Hyperinsulinemia]]
* [[Hyperinsulinemia/ja]]
* [[Resistin]]
* [[Resistin/ja]]
* [[Chronic stress]]
* [[Chronic stress/ja]]
* [[Inflammation#Interleukins and obesity|Systemic inflammation]]
* [[Inflammation/ja#Interleukins and obesity|全身性炎症]]
* [[Circadian rhythm#Obesity and diabetes|Circadian rhythm disruption]]
* [[Circadian rhythm/ja#Obesity and diabetes|概日リズムの乱れ]]
* [[Advanced glycation end-products]]
* [[Advanced glycation end-products/ja]]
* [[Polycystic ovary syndrome]]
* [[Polycystic ovary syndrome/ja]]
{{colend}}
{{colend}}
</div>
<div lang="en" dir="ltr" class="mw-content-ltr">
== さらに読む ==
== Further reading ==
{{refbegin}}
{{refbegin}}
* {{cite journal | vauthors = Reaven GM | title = The insulin resistance syndrome: definition and dietary approaches to treatment | journal = Annual Review of Nutrition | volume = 25 | pages = 391–406 | year = 2005 | pmid = 16011472 | doi = 10.1146/annurev.nutr.24.012003.132155 | s2cid = 24849146 | type = review }}
* {{cite journal | vauthors = Reaven GM | title = The insulin resistance syndrome: definition and dietary approaches to treatment | journal = Annual Review of Nutrition | volume = 25 | pages = 391–406 | year = 2005 | pmid = 16011472 | doi = 10.1146/annurev.nutr.24.012003.132155 | s2cid = 24849146 | type = review }}
* {{cite journal | vauthors = Rao G | title = Insulin resistance syndrome | journal = American Family Physician | volume = 63 | issue = 6 | pages = 1159–63, 1165–6 | date = March 2001 | pmid = 11277552 | url = http://www.aafp.org/afp/2001/0315/p1159.html | type = review | place = US }}
* {{cite journal | vauthors = Rao G | title = Insulin resistance syndrome | journal = American Family Physician | volume = 63 | issue = 6 | pages = 1159–63, 1165–6 | date = March 2001 | pmid = 11277552 | url = http://www.aafp.org/afp/2001/0315/p1159.html | type = review | place = US }}